MAR 1 2 2004



K040360 Special 510(k) EMU128S MARCH 8 2004 PAGE___OF___

Appendix C - 510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR § 807.92.

Name:

Cameron Mahon

Vice-President of Customer Satisfaction

Address:

Excel Tech, Ltd. 2568 Bristol Circle Oakville, Ontario Canada, L6H 5S1

Telephone:

(905) 829-5300

Fax:

(905) 829-5304

E-mail:

cmahon@xltek.com

Common Names:

EMU128S,

EMUI28 Switch Matrix, 128 Channel EEG Headbox

Classification Name:

Electroencephalograph

Predicate Devices:

Excel Tech Ltd. - 128 Channel EEG Headbox

Description:

The EMU128S is a digital electroencephalograph.

Substantial Equivalence:

The EMU128S is substantially equivalent in safety and effectiveness to the XLTEK 128 Channel EEG Headbox. There is no change to the acquisition, display, storage, or archiving of the EEG data. The change is the addition of a switch matrix. This switch matrix is an array of relays used to facilitate external devices

attachments to the wires that contact the patient.

Indications for Use:

The EMU128S is intended to be used as an electroencephalograph: to acquire, store, and archive electroencephalographic signals.





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Excel-Tech Ltd. c/o Mr. Cameron Mahon 2568 Bristol Circle Oakville, L6H5S1 Canada

APR -9 2012

Re: K040360

Trade/Device Name: EMU128S

Regulation Number: 21 CFR 882.1400 Regulation Name: Electroencephalograph

Regulatory Class: II

Product Code: GWQ, GYC

Dated (Date on orig SE ltr): January 30, 2004 Received (Date on orig SE ltr): February 13, 2004

Dear Mr. Mahon:

This letter corrects our substantially equivalent letter of March 12, 2004.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21) CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic, Neurological, and Ear. Nose and Throat Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

Indications for Use

510(k) Number ((if known): K04	0360		
Device Name:	EMU128S			
Indications For t	Jse:			
	s intended to be us stroencephalograph		encephalograpl	n: to acquire, store,
Prescription Use (Part 21 CFR 801 S	e X Subpart D)	AND/OR	Over-The-Cor	
		W THIS LINE-C	·	ANOTHER PAGE IF
Concurrence of CDRH, Office of Device Evaluation (ODE) Miriam C. Provost (Division Sign-Off) Division of General, Restorative,				
	and Neurologica	al Devices		Page 1 of
	Handa Number	$\nabla 010360$		